var data={"title":"Dihydroergotamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dihydroergotamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6035?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dihydroergotamine-drug-information\" class=\"drug drug_general\">see &quot;Dihydroergotamine: Drug information&quot;</a> and <a href=\"topic.htm?path=dihydroergotamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dihydroergotamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708702\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent drug therapy: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious and life-threatening peripheral ischemia have been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160464\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>D.H.E. 45;</li>\n      <li>Migranal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160465\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Migranal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057876\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Blocking Agent, Intranasal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Alpha-Adrenergic Blocking Agent, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antimigraine Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Ergot Alkaloid and Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057870\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dihydroergotamine-drug-information\" class=\"drug drug_general\">see &quot;Dihydroergotamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Migraine, intractable (&gt;72 hours) (status migrainosus):</b> Limited data available; optimal dose not established:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Premedicate with antiemetic (metoclopramide or prochlorperazine have been used)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low-dose regimen: <b>Note:</b> Improvement usually seen after 5 doses; some experts recommend administering 1 additional dose after headache subsides. If no improvement noted after 5 doses, discontinue therapy (Linder 1994; O'Brien 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to &lt;10 years: 0.1 mg/dose every 6 hours; continue therapy until headache-free up to a maximum of 8 doses per episode (Linder 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 10 to 12 years: 0.15 mg/dose every 6 hours; continue therapy until headache-free up to a maximum of 8 doses per episode.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &le;16 years: 0.2 mg/dose every 6 hours; continue therapy until headache-free up to a maximum of 8 doses per episode.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose regimen: <b>Note: </b>Improvement usually seen after 5 doses; some experts recommend administering 1 additional dose after headache subsides. If no improvement after 5 doses, discontinue therapy. Some experts recommend using an initial test dose (half of the appropriate dose for age and weight); if test dose tolerated, remainder of dose administered 30 minutes later (Kabbouche 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 6 to 9 years or Children &ge;10 years who weigh &lt;25 kg: 0.5 mg/dose every 8 hours; if improvement noted, continue therapy until headache-free up to a maximum of 15 doses per episode (Kabbouche 2009; Kabbouche 2015; Kacperski 2016; O'Brien 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;10 years weighing &gt;25 kg and Adolescents: 1 mg/dose every 8 hours; if improvement noted, continue therapy until headache-free up to a maximum of 15 doses per episode (Kabbouche 2009; Kabbouche 2015; Kacperski 2016; O'Brien 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Limited data available: Adolescents: 1 spray (0.5 mg) into each nostril (total dose: 1 mg) (Kliegman 2016); adult data suggests that dose should be repeated after 15 minutes for a total of 4 sprays (2 mg); maximum daily dose: 6 sprays (3 mg)/24-hour period; <b>Note:</b> Do not exceed 8 sprays (4 mg)/week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Migraine, cluster headache:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, SubQ: 1 mg at first sign of headache; repeat hourly to a maximum dose of 3 mg/day; maximum dose: 6 mg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 mg at first sign of headache; repeat hourly up to a maximum dose of 2 mg/day; maximum dose: 6 mg/week</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: 1 spray (0.5 mg) of nasal spray should be administered into each nostril; if needed, repeat after 15 minutes, up to a total of 4 sprays (2 mg). <b>Note:</b> Do not exceed 6 sprays (3 mg) in a 24-hour period and no more than 8 sprays (4 mg) in a week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Contraindicated in severe renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Dosage reductions are probably necessary but specific guidelines are not available; contraindicated in severe hepatic dysfunction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160440\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">D.H.E. 45: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Migranal: 4 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160426\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23082980\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=dihydroergotamine-drug-information\" class=\"drug drug_general\">see &quot;Dihydroergotamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Migranal nasal solution contains caffeine 10 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057879\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Children &ge;6 years, Adolescents, and Adults: Administer without dilution slowly over 2 to 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Adolescents and Adults: Prior to administration, the nasal spray applicator must be primed (pumped 4 times); in order to let the drug be absorbed through the skin in the nose, avoid deep inhalation through the nose while spraying or immediately after spraying; do not tilt head back. For best results, treatment should be initiated at the first symptom or sign of an attack; however, nasal spray can be used at any stage of a migraine attack. For further information, consult manufacturer labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM, SubQ: Adults: Administer without dilution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160460\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store below 25&deg;C (77&deg;F); do not refrigerate or freeze. Protect from light and heat.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasal spray: Prior to use, store below 25&deg;C (77&deg;F); do not refrigerate or freeze. Once spray applicator has been prepared, use within 8 hours; discard any unused solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057878\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Acute treatment of migraine headache with or without aura (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Acute treatment of migraine headache with or without aura and cluster headaches (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160514\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal spray:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, taste disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Stiffness, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngitis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Injection and nasal spray: Abdominal pain, anxiety, cerebral hemorrhage, cerebrovascular accident, coronary artery vasospasm, diaphoresis, diarrhea, dizziness, dyspnea, edema, fibrothorax (prolonged use), flushing, headache, hyperkinesia, hypertension, ischemic heart disease, muscle cramps, myalgia, myasthenia, myocardial infarction, palpitations, paresthesia, peripheral cyanosis, peripheral ischemia, retroperitoneal fibrosis (prolonged use), skin rash, subarachnoid hemorrhage, tremor, valvular sclerosis (associated with ergot alkaloids), ventricular fibrillation, ventricular tachycardia (transient)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160447\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dihydroergotamine or any component of the formulation; uncontrolled hypertension, ischemic heart disease, angina pectoris, history of MI, silent ischemia, or coronary artery vasospasm including Prinzmetal angina; hemiplegic or basilar migraine; peripheral vascular disease; sepsis; severe hepatic or renal dysfunction; following vascular surgery; avoid use within 24 hours of 5-hydroxytryptamine-1 (5HT<sub>1</sub>) receptor agonists (triptans), other serotonin agonists, or ergot-like agents; concurrent use of peripheral and central vasoconstrictors; concurrent use of potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); pregnancy, breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160430\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: May cause vasospastic reactions associated with symptoms of muscle pains, numbness, coldness, pallor, and cyanosis of the digits; myocardial and peripheral vascular ischemia have been reported.  In patients with compromised circulation, persistent vasospasm may result in gangrene or death. Evaluate patients who experience signs or symptoms suggestive of angina following administration for the presence of CAD or a predisposition to variant angina before receiving additional doses. Similarly, evaluate patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud syndrome. Significant hypertension has been reported (rarely) in patient with and without a history of hypertension. Adverse cardiac events, including acute myocardial infarction, life-threatening disturbance of cardiac rhythm, and death have been rarely reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have also occurred (in some cases resulted in fatalities) following use of the injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Do not give to patients with risk factors for CAD until a cardiovascular evaluation has been performed; if evaluation is satisfactory, the healthcare provider should administer the first dose and cardiovascular status should be periodically evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP3A4 inhibitors: <b>[US Boxed Warning]: Ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics); concomitant use associated with an increased risk of vasospasm leading to cerebral ischemia and/or ischemia of the extremities.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nasal Spray: Local irritation to nose and throat (usually transient and mild-moderate in severity) can occur; long-term consequences on nasal or respiratory mucosa have not been extensively evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856039\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause nausea; in pediatric patients, antiemetic prophylaxis (prochlorperazine or metoclopramide) 30 minutes prior to initial dihydroergotamine dose has been used (O'Brien 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160503\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160435\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13232&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Monoamine Oxidase Inhibitor): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity if selegiline, rasagiline, or safinamide is combined with a serotonin modulator. Use of transdermal selegiline with serotonin modulators is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Ergot Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Dihydroergotamine. Management: Avoid dihydroergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: May enhance the hypertensive effect of Ergot Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May increase the serum concentration of Ergot Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Dihydroergotamine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160437\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160449\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Dihydroergotamine is oxytocic and should not be used during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160429\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Efficacy in migraine is attributed to the activation of 5-HT<sub>1D</sub> receptors located on intracranial blood vessels resulting in vasoconstriction and/or activation of 5-HT<sub>1D</sub> receptors on sensory nerve endings of the trigeminal system resulting in the inhibition of pro-inflammatory neuropeptide release. Dihydroergotamine binds with high affinity to serotonin 5-HT<sub>1D&alpha;</sub>, 5-HT<sub>1D&beta;</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2C</sub> receptors, noradrenaline &alpha;<sub>2A</sub>, &alpha;<sub>2B</sub> and &alpha;<sub>1</sub> receptors, and dopamine D<sub>2L</sub> and D<sub>3</sub> receptors. Dihydroergotamine also possesses oxytocic properties.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160446\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~800 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic (one active metabolite, 8'-&beta;-hydroxydihydroergotamine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM, IV: 100%; Intranasal: 40% (Saper 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~9 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 24 minutes; IV: 1 to 2 minutes; Intranasal: 30 to 60 minutes (Saper 2006); SubQ 15 to 45 minutes (Schran 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily feces; urine (6% to 7% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160448\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (D.H.E. 45 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $1,412.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dihydroergotamine Mesylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $157.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Dihydroergotamine Mesylate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $494.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Migranal Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $551.17</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160451\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cervasal (BG);</li>\n      <li>Dergott (JP);</li>\n      <li>Detemes Retard (AT);</li>\n      <li>Detms (LU);</li>\n      <li>DH-Ergotamin (PL);</li>\n      <li>DHT (AR);</li>\n      <li>Diergo (BE);</li>\n      <li>Diergospray (FR);</li>\n      <li>Digalo (TW);</li>\n      <li>Dihydergot (AU, BE, BF, BJ, BR, CH, CI, CZ, ES, ET, GH, GM, GN, GR, ID, IL, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NL, NO, PE, SC, SD, SL, SN, TN, TR, TZ, UG, VE, ZA, ZM, ZW);</li>\n      <li>Dihydergot Sandoz (AT);</li>\n      <li>Dihydroergotamin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Dihydroergotaminum Methansulfonicum (PL);</li>\n      <li>Dihydroergotaminum Tartaricum (PL);</li>\n      <li>Ditamin (HR, PL);</li>\n      <li>Dystonal (BE);</li>\n      <li>Ergotamina (PY);</li>\n      <li>Ergovasan (AT);</li>\n      <li>Ginik (KR);</li>\n      <li>Hadermik/Migomik (VN);</li>\n      <li>Ikaran (FR, LU, VN);</li>\n      <li>Ikaran LP (FR);</li>\n      <li>Migranal (GB);</li>\n      <li>Migranil (IN);</li>\n      <li>Neomigran (HU, PL);</li>\n      <li>Orstanorm (FI, SE);</li>\n      <li>Parsel (MX);</li>\n      <li>Rayor (TW);</li>\n      <li>Seglor (AR, FR, IT, LU, TW);</li>\n      <li>Seglor Retard (PT);</li>\n      <li>Tamik (FR, VN);</li>\n      <li>Tonopan (MX);</li>\n      <li>Verladyn (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    D.H.E 45 (dihydroergotamine) [prescribing information]. Aliso Viejo, CA: Valeant Pharmaceuticals North America; September 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dihydroergotamine mesylate injection [prescribing information]. Minneapolis, MN: Perrigo; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kabbouche M. Pediatric Inpatient Headache Therapy: What is Available. <i>Headache</i>. 2015;55(10):1426-1429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/26517974/pubmed\" target=\"_blank\" id=\"26517974\">26517974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. <i>Headache</i>. 2009;49(1):106-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/19125879/pubmed\" target=\"_blank\" id=\"19125879\">19125879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kacperski J, Kabbouche MA, O'Brien HL, Weberding JL. The optimal management of headaches in children and adolescents. <i>Ther Adv Neurol Disord</i>. 2016;9(1):53-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/26788131/pubmed\" target=\"_blank\" id=\"26788131\">26788131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. <i>Headache</i>. 1994;34(10):578-580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/7843951/pubmed\" target=\"_blank\" id=\"7843951\">7843951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Migergot (ergotamine tartrate and caffeine) [prescribing information]. Glendale, WI: Crealta Pharmaceuticals LLC; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Migranal (dihydroergotamine mesylate) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Brien HL, Kabbouche MA, Hershey AD. Treatment of acute migraine in the pediatric population. <i>Curr Treat Options Neurol</i>. 2010;12(3):178-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/20842580/pubmed\" target=\"_blank\" id=\"20842580\">20842580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. <i>Headache</i>. 2006;46(Suppl 4):171-181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/17078849/pubmed\" target=\"_blank\" id=\"17078849\">17078849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schran HF, Tse FL. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1985;23(1):1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dihydroergotamine-pediatric-drug-information/abstract-text/3988387/pubmed\" target=\"_blank\" id=\"3988387\">3988387</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13232 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708702\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F160464\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F160465\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057876\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057870\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F160440\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F160426\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F23082980\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057879\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F160460\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057878\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F160514\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F160447\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F160430\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856039\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F160503\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F160435\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F160437\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F160449\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F160429\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F160446\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F160448\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F160451\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13232|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dihydroergotamine-drug-information\" class=\"drug drug_general\">Dihydroergotamine: Drug information</a></li><li><a href=\"topic.htm?path=dihydroergotamine-patient-drug-information\" class=\"drug drug_patient\">Dihydroergotamine: Patient drug information</a></li></ul></div></div>","javascript":null}